[{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ADC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab tesirine","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Camidanlumab Tesirine","moa":"CD25","graph1":"Oncology","graph2":"Phase II","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Antibody-drug conjugates","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ADC Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"ADC Therapeutics \/ ADC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"ADC Therapeutics \/ ADC Therapeutics"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Camidanlumab Tesirine","moa":"CD25","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Camidanlumab tesirine","moa":"CD25","graph1":"Oncology","graph2":"Phase II","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ ADC Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"ADC Therapeutics \/ ADC Therapeutics"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Camidanlumab Tesirine","moa":"CD25","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Camidanlumab tesirine","moa":"CD25","graph1":"Oncology","graph2":"Phase II","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Sterling Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Loncastuximab tesirine-lpyl","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Sterling Pharma Solutions","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Sterling Pharma Solutions"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Deerfield Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Deerfield Partners","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Deerfield Partners"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine-lpyl","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"Loncastuximab Tesirine","moa":"DNA chain","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"ADC Therapeutics \/ HealthCare Royalty","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ HealthCare Royalty"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine-lpyl","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Overland Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Overland Pharmaceuticals"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"BerGenBio ASA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"AXL receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ BerGenBio","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ BerGenBio"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Owl Rock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ADC Therapeutics \/ Owl Rock","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Owl Rock"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Sobi"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Biocytogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ADC Therapeutics \/ ADC Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"ADC Therapeutics \/ ADC Therapeutics"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"IntoCell","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ADC Therapeutics \/ ADC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"ADC Therapeutics \/ ADC Therapeutics"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Overland Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therapeutics \/ Overland Pharmaceuticals"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Loncastuximab Tesirine","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ADC Therapeutics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by ADC Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
